Get the Stockscreener App
10.99
3.19%
0.34
Trevi Therapeutics Inc stock is traded at $10.99, with a volume of 1.24M.
It is up +3.19% in the last 24 hours and up +3.19% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$10.65
Open:
$10.59
24h Volume:
1.24M
Relative Volume:
0.57
Market Cap:
$1.41B
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-37.90
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
-3.34%
1M Performance:
+3.19%
6M Performance:
+77.83%
1Y Performance:
+302.56%
1-Day Range:
$10.46
$11.21
1-Week Range:
$10.46
$11.67
52-Week Range:
$2.36
$12.30
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
10.99 | 1.37B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat
Leerink Partnrs Has Bullish Outlook for TRVI FY2025 Earnings - MarketBeat
B. Riley Increases Earnings Estimates for Trevi Therapeutics - MarketBeat
Leerink Partners Maintains Trevi Therapeutics (TRVI) Outperform Recommendation - Nasdaq
TRVI's Price Target Raised by Leerink Partners to $16.00, Mainta - GuruFocus
What is B. Riley's Forecast for TRVI Q1 Earnings? - MarketBeat
Can Trevi Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Fed Impact & Stock Portfolio Risk Management - newser.com
Analyzing drawdowns of Trevi Therapeutics Inc. with statistical toolsBreakout Watch & Verified High Yield Trade Plans - newser.com
How resilient is Trevi Therapeutics Inc. stock in market downturns2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook By Investing.com - Investing.com South Africa
Is now a turning point for Trevi Therapeutics Inc.Insider Selling & Weekly Top Gainers Trade List - newser.com
Technical signs of recovery in Trevi Therapeutics Inc.Trade Risk Report & Fast Exit/Entry Strategy Plans - newser.com
Is Trevi Therapeutics Inc. stock a buy for dividend growthTrade Performance Summary & Safe Entry Zone Identification - newser.com
Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook - Investing.com Canada
Should I hold or sell Trevi Therapeutics Inc. stock in 2025CEO Change & Consistent Profit Trade Alerts - newser.com
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk (NASDAQ:TRVI) - Seeking Alpha
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Strong Earnings - MarketBeat
Momentum divergence signals in Trevi Therapeutics Inc. chartMarket Sentiment Summary & Reliable Entry Point Alerts - newser.com
What MACD signals say about Trevi Therapeutics Inc.July 2025 WrapUp & Entry Point Strategy Guides - newser.com
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension - Yahoo Finance
How Trevi Therapeutics’ (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations - Yahoo Finance
Oppenheimer Maintains Trevi Therapeutics (TRVI) Outperform Recommendation - Nasdaq
Trevi Therapeutics (NASDAQ:TRVI) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Ca - GuruFocus
Cantor Fitzgerald reiterates Overweight rating on Trevi Therapeutics stock By Investing.com - Investing.com Canada
Oppenheimer Raises Price Target for Trevi Therapeutics (TRVI) to $24 | TRVI Stock News - GuruFocus
Historical volatility pattern of Trevi Therapeutics Inc. visualizedMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Leerink Partners Begins Coverage on Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
TRVI: Morgan Stanley Raises Price Target Amid Continued Overweig - GuruFocus
Oppenheimer Adjusts Trevi Therapeutics PT to $24 From $23, Maintains Outperform Rating - MarketScreener
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2025 Earnings Call Transcript - Insider Monkey
Trevi Therapeutics (TRVI) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Oppenheimer raises Trevi Therapeutics stock price target on chronic cough program expansion - Investing.com Canada
Clear Street raises Trevi Therapeutics stock price target to $21 on clinical progress - Investing.com Canada
Clear Street Maintains Trevi Therapeutics (TRVI) Buy Recommendation - Nasdaq
TRVI: Analyst Maintains 'Buy' Rating and Raises Price Target | T - GuruFocus
Why retail investors pile into Trevi Therapeutics Inc. stockJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - Fundação Cultural do Pará
Trevi Therapeutics Inc (TRVI) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Decoding Trevi Therapeutics Inc (TRVI): A Strategic SWOT Insight - GuruFocus
Trevi Therapeutics Inc (TRVI) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Trevi Therapeutics Inc (TRVI) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Trevi Therapeutics Reports Q3 2025 Financials and Updates - TipRanks
Trevi Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Can Trevi Therapeutics Inc. stock reach $100 price target2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
Trevi Therapeutics Trims Losses And Banks On Future Trials - Finimize
Earnings call transcript: Trevi Therapeutics reports Q3 2025 results with EPS surprise - Investing.com Australia
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):